Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia

Dual orexin receptor antagonists (DORAs) represent a novel type of sleep medication that provide an alternative to the traditionally used positive allosteric gamma-aminobutyric acid (GABA)-A receptor modulators. Daridorexant is a new DORA that exhibited in phase 3 trials in insomnia not only a benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Roch, Catherine, Bergamini, Giorgio, Steiner, Michel A., Clozel, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455402/
https://www.ncbi.nlm.nih.gov/pubmed/34415378
http://dx.doi.org/10.1007/s00213-021-05954-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455402/
https://www.ncbi.nlm.nih.gov/pubmed/34415378
http://dx.doi.org/10.1007/s00213-021-05954-0

Ejemplares similares